特兰胺酸 - - 一种具有局限性的有前途的静血剂:叙述性综述
Dong Joon Kim1, Su Yeon Cho1, Ki Tae Jung1
1Department of Anesthesiology and Pain Medicine, Chosun University Hospital, Chosun University College of Medicine and Medical School, Gwangju, Korea.
Korean journal of anesthesiology
|August 21, 2023
概括
特兰胺酸 (TXA) 有效地减少了在各种医疗过程中流失的血液. 然而,新兴研究强调了潜在的风险和局限性,需要仔细考虑其长期益处和适当的使用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 医学 医学 医学 医学 医学
- 血液学 血液学 血液学
背景情况:
- 特兰胺酸 (TXA) 是一种广泛使用的抗纤维解质剂,用于控制出血.
- 从历史上来看,在流血,血友病和手术/创伤环境中应用.
- 已证明在减少血液损失和输血需求方面具有有效性.
研究的目的:
- 审查特兰胺酸的确定的临床应用.
- 探索TXA在各种医疗领域的新兴用途.
- 总结有关TXA相关的限制和潜在风险的当前数据.
主要方法:
- 现有文献的叙述性审查.
- 从临床试验和研究中得出的结合结果.
- 对TXA的疗效,安全性和限制进行分析.
主要成果:
- 在多种手术和创伤场景中,TXA有效地减少了血液流失.
- 越来越多的证据支持TXA在产后出血,心脏,骨科和神经外科手术中的使用.
- 最近的试验表明TXA长期益处的潜在风险和局限性.
结论:
- 特兰胺酸仍然是控制出血的宝贵工具.
- 扩展适应症需要对其风险和益处有全面的了解.
- 需要进一步的研究来澄清安全和适当的长期TXA利用.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
751
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
751
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
562
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
562
Disorders of Hemostasis
989
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
989
Therapeutic Index
4.3K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.3K


